Venkatraman Seshan

Memorial Sloan Kettering Cancer Center — United States

Medicine · Health Sciences

58h-index16.1kcitations422works1.52yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Lymphoma Diagnosis and Treatment(87), Cancer Genomics and Diagnostics(66), Thyroid Cancer Diagnosis and Treatment(64), Lung Cancer Treatments and Mutations(45), Chronic Lymphocytic Leukemia Research(37)

Publications421 total

Supplemental Table 1, Supplemental Table 2, Supplemental Table 3, Supplemental Table 6, Supplemental Table 7, Supplemental Figure 1, and Supplemental Figure 2 from Multiple Primary Cancers in Patients Undergoing Tumor-Normal Sequencing Define Novel Associations
2025Open Access
Data from Multiple Primary Cancers in Patients Undergoing Tumor-Normal Sequencing Define Novel Associations
2025Open Access
Supplemental Materials and Methods from Multiple Primary Cancers in Patients Undergoing Tumor-Normal Sequencing Define Novel Associations
2025Open Access
Supplemental Table 5 from Multiple Primary Cancers in Patients Undergoing Tumor-Normal Sequencing Define Novel Associations
2025Open Access
Supplemental Table 4 from Multiple Primary Cancers in Patients Undergoing Tumor-Normal Sequencing Define Novel Associations
2025Open Access
Supplementary Data1 from Tumor miRNA Signatures Associate with Outcomes of Patients with Stage II/III Melanoma
2025Open Access
Supplementary Figures1 from Tumor miRNA Signatures Associate with Outcomes of Patients with Stage II/III Melanoma
2025Open Access
Supplementary Figure from Accounting for Delayed Entry in Analyses of Overall Survival in Clinico-Genomic Databases
2025Open Access
Supplementary Figure from Accounting for Delayed Entry in Analyses of Overall Survival in Clinico-Genomic Databases
2025Open Access
Supplementary Figure from Accounting for Delayed Entry in Analyses of Overall Survival in Clinico-Genomic Databases
2025Open Access
Supplementary Figure from Accounting for Delayed Entry in Analyses of Overall Survival in Clinico-Genomic Databases
2025Open Access
Supplementary Figure from Accounting for Delayed Entry in Analyses of Overall Survival in Clinico-Genomic Databases
2025Open Access
Supplementary Data from Accounting for Delayed Entry in Analyses of Overall Survival in Clinico-Genomic Databases
2025Open Access
Data from Accounting for Delayed Entry in Analyses of Overall Survival in Clinico-Genomic Databases
2025Open Access
Table S3 from Genomic and Transcriptomic Characteristics of Metastatic Thyroid Cancers with Exceptional Responses to Radioactive Iodine Therapy
2025Open Access
Table S6 from Genomic and Transcriptomic Characteristics of Metastatic Thyroid Cancers with Exceptional Responses to Radioactive Iodine Therapy
2025Open Access
Figure S2 from Genomic and Transcriptomic Characteristics of Metastatic Thyroid Cancers with Exceptional Responses to Radioactive Iodine Therapy
2025Open Access
Figure S1 from Genomic and Transcriptomic Characteristics of Metastatic Thyroid Cancers with Exceptional Responses to Radioactive Iodine Therapy
2025Open Access
Table S5 from Genomic and Transcriptomic Characteristics of Metastatic Thyroid Cancers with Exceptional Responses to Radioactive Iodine Therapy
2025Open Access
Table S2 from Genomic and Transcriptomic Characteristics of Metastatic Thyroid Cancers with Exceptional Responses to Radioactive Iodine Therapy
2025Open Access
page 1 of 22Next →

Frequent Co-authors

Valerie W. Rusch(11), Marc Ladanyi(8), Luc G.T. Morris(7), Raja M. Flores(6), Michael F. Berger(6), Timothy A. Chan(6), Maureen F. Zakowski(5), William D. Travis(5), Manjit S. Bains(5), Ian Ganly(5), Mark G. Kris(4), Agnès Viale(4), Nadeem Riaz(4), A. Ari Hakimi(4), Chris Sander(4), Bernard J. Park(4), Nabil P. Rizk(4), James A. Fagin(4), Ronglai Shen(4), Owen A. O’Connor(4)